PE20070012A1 - Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-clorofenil)[4-(4-piridilmetil) ftalazin-1-ilo] micronizado, y sus sales - Google Patents
Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-clorofenil)[4-(4-piridilmetil) ftalazin-1-ilo] micronizado, y sus salesInfo
- Publication number
- PE20070012A1 PE20070012A1 PE2006000620A PE2006000620A PE20070012A1 PE 20070012 A1 PE20070012 A1 PE 20070012A1 PE 2006000620 A PE2006000620 A PE 2006000620A PE 2006000620 A PE2006000620 A PE 2006000620A PE 20070012 A1 PE20070012 A1 PE 20070012A1
- Authority
- PE
- Peru
- Prior art keywords
- ilo
- micronized
- chlorophenyl
- immediate release
- drug load
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A UNA FORMULACION FARMACEUTICA SOLIDA DE LIBERACION INMEDIATA Y CON UNA CARGA DE DROGA ELEVADA QUE COMPRENDE: A) AL MENOS 50% EN PESO DE LA FORMULACION TOTAL DEL PRINCIPIO ACTIVO (4-CLOROFENIL)[4-(4-PIRIDILMETIL)-FTALAZIN-1-ILO] MICRONIZADO, SIENDO PREFERIDA BAJO LA FORMA DE SAL SUCCINATO Y B) AL MENOS UN DESINTEGRANTE EN BASE A CARBOXIMETILCELULOSA TAL COMO CROSCARMELOSA SODICA EN UNA CANTIDAD DE 1-25% EN PESO DE LA FORMULACION. EN DONDE EL PRINCIPIO ACTIVO SE DISUELVE A PARTIR DE DICHA FORMULACION EN 30 MINUTOS Y TIENE UN VALOR d90 DE A LO SUMO 25um. TAMBIEN SE REFIERE A UNA PROCESO DE PREPARACION. ESTA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE LA PSORIASIS, RETINOPLASTIAS, ENFERMEDADES NEOPLASICAS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05090167A EP1731154A1 (en) | 2005-06-07 | 2005-06-07 | Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl)|4-(4-pyridylmethyl)pht halazin-1-yl| and salts thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20070012A1 true PE20070012A1 (es) | 2007-02-07 |
Family
ID=34938468
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2006000620A PE20070012A1 (es) | 2005-06-07 | 2006-06-06 | Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-clorofenil)[4-(4-piridilmetil) ftalazin-1-ilo] micronizado, y sus sales |
Country Status (22)
Country | Link |
---|---|
EP (2) | EP1731154A1 (es) |
JP (1) | JP2008542421A (es) |
KR (1) | KR20080017443A (es) |
CN (1) | CN101242841A (es) |
AR (1) | AR054377A1 (es) |
AU (1) | AU2006256853A1 (es) |
BR (1) | BRPI0611818A2 (es) |
CA (1) | CA2610977A1 (es) |
CR (1) | CR9577A (es) |
CU (1) | CU20070272A7 (es) |
DO (1) | DOP2006000128A (es) |
EC (1) | ECSP078037A (es) |
GT (1) | GT200600243A (es) |
IL (1) | IL187906A0 (es) |
MX (1) | MX2007015495A (es) |
NO (1) | NO20080066L (es) |
PE (1) | PE20070012A1 (es) |
RU (1) | RU2007147953A (es) |
TW (1) | TW200716114A (es) |
UY (1) | UY29585A1 (es) |
WO (1) | WO2006131394A1 (es) |
ZA (1) | ZA200800113B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1958615A1 (en) * | 2007-02-13 | 2008-08-20 | Bayer Schering Pharma Aktiengesellschaft | Solid pharmaceutical formulations of a homogeneous dispersion of active principles having pH-dependent solubility |
EP1958616A1 (en) * | 2007-02-13 | 2008-08-20 | Bayer Schering Pharma Aktiengesellschaft | Pharmaceutical formulations of 1-[4-chloroanilino]-4-[4-pyridylmethyl] phthalazine or salts thereof |
WO2016020901A1 (en) | 2014-08-07 | 2016-02-11 | Acerta Pharma B.V. | Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
US6482802B1 (en) | 1998-05-11 | 2002-11-19 | Endowment For Research In Human Biology, Inc. | Use of neomycin for treating angiogenesis-related diseases |
-
2005
- 2005-06-07 EP EP05090167A patent/EP1731154A1/en not_active Withdrawn
-
2006
- 2006-06-06 CN CNA2006800294846A patent/CN101242841A/zh active Pending
- 2006-06-06 BR BRPI0611818-6A patent/BRPI0611818A2/pt not_active IP Right Cessation
- 2006-06-06 KR KR1020087000234A patent/KR20080017443A/ko not_active Application Discontinuation
- 2006-06-06 WO PCT/EP2006/005601 patent/WO2006131394A1/en active Application Filing
- 2006-06-06 RU RU2007147953/15A patent/RU2007147953A/ru not_active Application Discontinuation
- 2006-06-06 MX MX2007015495A patent/MX2007015495A/es not_active Application Discontinuation
- 2006-06-06 TW TW095120061A patent/TW200716114A/zh unknown
- 2006-06-06 CU CU20100122A patent/CU20070272A7/es unknown
- 2006-06-06 CA CA002610977A patent/CA2610977A1/en not_active Abandoned
- 2006-06-06 JP JP2008515152A patent/JP2008542421A/ja active Pending
- 2006-06-06 PE PE2006000620A patent/PE20070012A1/es not_active Application Discontinuation
- 2006-06-06 GT GT200600243A patent/GT200600243A/es unknown
- 2006-06-06 AU AU2006256853A patent/AU2006256853A1/en not_active Abandoned
- 2006-06-06 EP EP06762011A patent/EP1888073A1/en not_active Withdrawn
- 2006-06-07 DO DO2006000128A patent/DOP2006000128A/es unknown
- 2006-06-07 UY UY29585A patent/UY29585A1/es not_active Application Discontinuation
- 2006-06-07 AR ARP060102364A patent/AR054377A1/es unknown
-
2007
- 2007-12-05 IL IL187906A patent/IL187906A0/en unknown
- 2007-12-07 CR CR9577A patent/CR9577A/es not_active Application Discontinuation
- 2007-12-19 EC EC2007008037A patent/ECSP078037A/es unknown
-
2008
- 2008-01-04 NO NO20080066A patent/NO20080066L/no not_active Application Discontinuation
- 2008-01-04 ZA ZA200800113A patent/ZA200800113B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
JP2008542421A (ja) | 2008-11-27 |
CN101242841A (zh) | 2008-08-13 |
TW200716114A (en) | 2007-05-01 |
MX2007015495A (es) | 2008-02-22 |
CA2610977A1 (en) | 2006-12-14 |
ECSP078037A (es) | 2008-01-23 |
UY29585A1 (es) | 2007-01-31 |
ZA200800113B (en) | 2009-07-29 |
DOP2006000128A (es) | 2006-12-15 |
CU20070272A7 (es) | 2010-09-30 |
IL187906A0 (en) | 2008-03-20 |
BRPI0611818A2 (pt) | 2010-09-28 |
RU2007147953A (ru) | 2009-07-20 |
KR20080017443A (ko) | 2008-02-26 |
CR9577A (es) | 2008-03-06 |
GT200600243A (es) | 2007-07-16 |
WO2006131394A1 (en) | 2006-12-14 |
EP1888073A1 (en) | 2008-02-20 |
AU2006256853A1 (en) | 2006-12-14 |
NO20080066L (no) | 2008-03-06 |
AR054377A1 (es) | 2007-06-20 |
EP1731154A1 (en) | 2006-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017003445A1 (es) | Formas solidas y formulaciones de compuestos de imidazopirazina. | |
BR112013032122A2 (pt) | liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos | |
PA8629501A1 (es) | Tabletas dispersables que comprenden un derivado de acido benzoico | |
AR078846A1 (es) | Composicion para el tratamiento de la enfermedad de alzheimer | |
NI200700064A (es) | Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3- trifluorometil-fenil)- ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos. | |
PE20071037A1 (es) | SALES Y FORMULACIONES DE 1-[5-(4-AMINO-7-ISOPROPIL-7H-PIRROLO[2,3-d]PIRIMIDIN-5-CARBONIL)-2-METOXI-FENIL]-3-(2,4-DICLORO-FENIL)-UREA | |
PE20140960A1 (es) | Formulaciones que comprenden un inhibidor de dpp4 | |
HN2011000699A (es) | El compuesto (s)-1-({4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il}-amida) de 2-amida del acido pirrolidin-1,2-dicarboxilico en forma libre o de sal y composiciones y composicion farmaceutica que lo contiene. | |
AR072755A2 (es) | Comprimido de carga de droga alta del compuesto 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida | |
ECSP088973A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
ECSP066990A (es) | Formulaciones con liberación controlada de principio activo que contienen vardenafilo | |
GT200600096A (es) | Composicion farmaceutica para el tratamiento del cancer | |
PA8586501A1 (es) | Tabletas dispersables que comprenden un derivado de acido benzoico | |
ECSP12011699A (es) | Tableta | |
CL2009000241A1 (es) | Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer. | |
TN2012000371A1 (en) | Pyrazole compounds as crth2 antagonists | |
CO6491060A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
AR124688A2 (es) | Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo | |
AR067328A1 (es) | Formas amorfas estabilizadas de mesilato de imatinib | |
AR076300A1 (es) | Derivados de pirimidin imidazoles sustituidos, inhibidores de gsk3, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del alzheimer, enfermedades neurodegenerativas agudas, diabetes y otras enfermedades. | |
PE20151607A1 (es) | Formulaciones de compuestos organicos | |
PE20070012A1 (es) | Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-clorofenil)[4-(4-piridilmetil) ftalazin-1-ilo] micronizado, y sus sales | |
NI200700031A (es) | Formulaciones de ácido hidroxamico suberoilanilida y procedimientos para la producción de las mismas | |
PE20091900A1 (es) | Una formulacion farmaceutica solida | |
AR056369A1 (es) | Compuestos derivados de quinazolina y composicion farmaceutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |